JP6758195B2 - 併用ベースの治療方法 - Google Patents

併用ベースの治療方法 Download PDF

Info

Publication number
JP6758195B2
JP6758195B2 JP2016563904A JP2016563904A JP6758195B2 JP 6758195 B2 JP6758195 B2 JP 6758195B2 JP 2016563904 A JP2016563904 A JP 2016563904A JP 2016563904 A JP2016563904 A JP 2016563904A JP 6758195 B2 JP6758195 B2 JP 6758195B2
Authority
JP
Japan
Prior art keywords
days
inhibitor
topoisomerase
cancer
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016563904A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017502091A (ja
JP2017502091A5 (OSRAM
Inventor
ウテ ホック，
ウテ ホック，
ナンシー マリー バーンズ，
ナンシー マリー バーンズ，
デボラ エイチ． チャリッチ，
デボラ エイチ． チャリッチ，
Original Assignee
ネクター セラピューティクス
ネクター セラピューティクス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52469293&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6758195(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ネクター セラピューティクス, ネクター セラピューティクス filed Critical ネクター セラピューティクス
Publication of JP2017502091A publication Critical patent/JP2017502091A/ja
Publication of JP2017502091A5 publication Critical patent/JP2017502091A5/ja
Application granted granted Critical
Publication of JP6758195B2 publication Critical patent/JP6758195B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2016563904A 2014-01-14 2015-01-13 併用ベースの治療方法 Active JP6758195B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461927376P 2014-01-14 2014-01-14
US61/927,376 2014-01-14
US201462080775P 2014-11-17 2014-11-17
US62/080,775 2014-11-17
PCT/US2015/011239 WO2015108876A1 (en) 2014-01-14 2015-01-13 Combination-based treatment method

Publications (3)

Publication Number Publication Date
JP2017502091A JP2017502091A (ja) 2017-01-19
JP2017502091A5 JP2017502091A5 (OSRAM) 2018-01-18
JP6758195B2 true JP6758195B2 (ja) 2020-09-23

Family

ID=52469293

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016563904A Active JP6758195B2 (ja) 2014-01-14 2015-01-13 併用ベースの治療方法

Country Status (8)

Country Link
US (2) US10653689B2 (OSRAM)
EP (1) EP3094331B1 (OSRAM)
JP (1) JP6758195B2 (OSRAM)
KR (1) KR102501566B1 (OSRAM)
AU (1) AU2015206667B2 (OSRAM)
CA (1) CA2934552C (OSRAM)
MX (1) MX386070B (OSRAM)
WO (1) WO2015108876A1 (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102611382B1 (ko) 2018-09-19 2023-12-07 삼성디스플레이 주식회사 터치 감지 유닛과 그를 포함하는 표시 장치
WO2025186213A1 (en) 2024-03-04 2025-09-12 Debiopharm International S.A. Combination of a wee1 inhibitor and a topoisomerase 1 inhibitor

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120073370A (ko) * 2003-09-17 2012-07-04 넥타르 테라퓨틱스 다분지형 고분자 전구약물
KR20090130156A (ko) * 2004-09-22 2009-12-17 화이자 인코포레이티드 폴리(에이디피-리보오스) 폴리머라제 저해제를 포함하는 치료 배합물
JP2006124351A (ja) 2004-11-01 2006-05-18 Yakult Honsha Co Ltd 徐放性抗腫瘍剤組成物
DK2338487T3 (da) 2006-01-17 2013-12-09 Abbvie Bahamas Ltd Kombinationsterapi med PARP-inhibitorer
WO2007092646A2 (en) 2006-02-09 2007-08-16 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
EP2038654A4 (en) * 2006-06-12 2010-08-11 Bipar Sciences Inc METHOD FOR THE TREATMENT OF DISEASES WITH PARP INHIBITORS
AU2008321128A1 (en) * 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents
US20090149397A1 (en) 2007-12-07 2009-06-11 Bipar Sciences Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors
CA3063465C (en) 2009-11-18 2023-01-03 Nektar Therapeutics Acid salt forms of polymer-drug conjugates and alkoxylation methods
AU2013202947B2 (en) * 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan

Also Published As

Publication number Publication date
WO2015108876A1 (en) 2015-07-23
EP3094331B1 (en) 2017-12-27
EP3094331A1 (en) 2016-11-23
KR102501566B1 (ko) 2023-02-17
KR20160106086A (ko) 2016-09-09
US20200237747A1 (en) 2020-07-30
JP2017502091A (ja) 2017-01-19
CA2934552A1 (en) 2015-07-23
AU2015206667B2 (en) 2020-05-14
CA2934552C (en) 2021-03-30
AU2015206667A1 (en) 2016-07-07
US20160339013A1 (en) 2016-11-24
MX386070B (es) 2025-03-18
MX2016009167A (es) 2016-09-09
US10653689B2 (en) 2020-05-19

Similar Documents

Publication Publication Date Title
JP6963385B2 (ja) 抗ＣＴＬＡ−４抗体又は抗ＰＤ−１抗体との併用におけるＩＬ−２Ｒβ選択的作動薬
AU2016310476B2 (en) Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
ES2982897T3 (es) Uso del inhibidor de la telomerasa imetelstat para el tratamiento de trastornos mieloproliferativos y neoplasias mieloproliferativas
JP6076317B2 (ja) 対象において持続的治療薬濃度を実現するための組成物及び方法
KR20170055474A (ko) 길항 pd-1 압타머 및 암 요법 관련 적용에서의 그의 적용
JP6223995B2 (ja) カンプトテシン類と抗癌効果増強剤の結合した高分子化合物及びその用途
CN111587115A (zh) 协同癌症治疗
JP6758195B2 (ja) 併用ベースの治療方法
Agrawal et al. GEM 231, a second-generation antisense agent complementary to protein kinase A RIα subunit, potentiates antitumor activity of irinotecan in human colon, pancreas, prostate and lung cancer xenografts
JP6138140B2 (ja) 癌患者の治療
Di Paolo et al. Clinical pharmacokinetics of irinotecan-based chemotherapy in colorectal cancer patients
KR102276343B1 (ko) 혈관차단제로 유용한 벤조페논 티아졸 유도체 및 토포이소머라제 억제제를 포함하는 암의 예방 또는 치료용 약학적 조합물
CN107921282A (zh) 选择性抑制肠羧酸酯酶2酶活性的组合物及方法
Liu et al. Recent advances and developments in the inhibitors of DNA topoisomerases
Braun Capecitabine in colorectal cancer
HK1155378A (en) Use of idrabiotaparinux for decreasing the incidence of bleedings during an antithrombotic treatment

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190131

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190425

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190731

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191001

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191226

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200331

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200709

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200804

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200901

R150 Certificate of patent or registration of utility model

Ref document number: 6758195

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250